GSK EBITDA Margin 2010-2023 | GSK
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for GSK (GSK) over the last 10 years. The current EBITDA margin for GSK as of March 31, 2023 is .
| GSK EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-03-31 |
$31.59B |
$9.22B |
29.18% |
| 2022-12-31 |
$36.27B |
$10.61B |
29.26% |
| 2022-09-30 |
$43.90B |
$10.40B |
23.68% |
| 2022-06-30 |
$47.19B |
$11.98B |
25.39% |
| 2022-03-31 |
$49.80B |
$13.17B |
26.45% |
| 2021-12-31 |
$46.91B |
$11.30B |
24.09% |
| 2021-09-30 |
$45.57B |
$15.04B |
33.01% |
| 2021-06-30 |
$44.22B |
$14.21B |
32.13% |
| 2021-03-31 |
$42.37B |
$13.02B |
30.72% |
| 2020-12-31 |
$43.78B |
$13.01B |
29.72% |
| 2020-09-30 |
$43.78B |
$10.50B |
23.97% |
| 2020-06-30 |
$44.19B |
$10.49B |
23.75% |
| 2020-03-31 |
$44.77B |
$11.30B |
25.23% |
| 2019-12-31 |
$43.10B |
$11.87B |
27.54% |
| 2019-09-30 |
$38.25B |
$11.79B |
30.81% |
| 2019-06-30 |
$37.22B |
$11.71B |
31.45% |
| 2019-03-31 |
$37.13B |
$10.13B |
27.28% |
| 2018-12-31 |
$41.14B |
$9.80B |
23.81% |
| 2018-09-30 |
$44.61B |
$7.91B |
17.74% |
| 2018-06-30 |
$44.33B |
$8.21B |
18.53% |
| 2018-03-31 |
$43.74B |
$8.28B |
18.93% |
| 2017-12-31 |
$38.90B |
$7.75B |
19.91% |
| 2017-09-30 |
$38.68B |
$9.32B |
24.09% |
| 2017-06-30 |
$37.79B |
$6.28B |
16.63% |
| 2017-03-31 |
$37.35B |
$6.74B |
18.05% |
| 2016-09-30 |
$37.82B |
$17.98B |
47.53% |
| 2016-06-30 |
$37.41B |
$19.31B |
51.62% |
| 2016-03-31 |
$37.06B |
$19.01B |
51.30% |
| 2015-12-31 |
$36.65B |
$18.34B |
50.06% |
| 2015-09-30 |
$36.35B |
$5.64B |
15.51% |
| 2015-06-30 |
$35.97B |
$4.27B |
11.88% |
| 2015-03-31 |
$36.42B |
$6.61B |
18.15% |
| 2014-12-31 |
$37.35B |
$8.19B |
21.93% |
| 2014-09-30 |
$39.27B |
$10.17B |
25.89% |
| 2014-06-30 |
$40.67B |
$12.05B |
29.62% |
| 2014-03-31 |
$41.36B |
$12.63B |
30.55% |
| 2013-12-31 |
$41.79B |
$12.92B |
30.92% |
| 2013-09-30 |
$41.34B |
$13.98B |
33.82% |
| 2013-06-30 |
$41.34B |
$13.39B |
32.40% |
| 2013-03-31 |
$41.38B |
$13.42B |
32.43% |
| 2012-12-31 |
$42.22B |
$13.76B |
32.60% |
| 2012-09-30 |
$42.43B |
$14.19B |
33.45% |
| 2012-06-30 |
$43.22B |
$14.95B |
34.60% |
| 2012-03-31 |
$43.96B |
$15.48B |
35.22% |
| 2011-12-31 |
$43.79B |
$15.06B |
34.40% |
| 2011-09-30 |
$44.43B |
$11.16B |
25.11% |
| 2011-06-30 |
$43.69B |
$11.09B |
25.38% |
| 2011-03-31 |
$41.94B |
$6.99B |
16.68% |
| 2010-12-31 |
$42.68B |
$7.83B |
18.34% |
| 2010-09-30 |
$44.26B |
$11.23B |
25.38% |
| 2010-06-30 |
$44.80B |
$11.53B |
25.74% |
| 2010-03-31 |
$46.13B |
$15.88B |
34.43% |
| 2009-12-31 |
$44.58B |
$15.34B |
34.40% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$69.205B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
